Upadacitinib for Ulcerative Colitis

This trial aims to determine if the oral medication upadacitinib can safely and effectively treat acute severe ulcerative colitis (ASUC) in hospitalized adults. Researchers seek to discover if upadacitinib can provide benefits without corticosteroids and reduce the need for surgery or additional treatments within two weeks. Participants will be compared to historical patients who received standard treatments, such as intravenous corticosteroids and infliximab. Adults hospitalized with ASUC who have not used upadacitinib before and have had ulcerative colitis for at least 90 days may be suitable for this trial. As a Phase 4 trial, this research helps to understand how the already FDA-approved and effective treatment benefits more patients.

The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants should not use certain strong medications that affect liver enzymes or herbal therapies within 30 days before starting the trial. It's best to discuss your current medications with the trial team to see if any adjustments are needed.

Research has shown that upadacitinib is generally safe for treating ulcerative colitis. Several studies have examined its long-term safety, finding that most patients tolerate it well. For instance, a study lasting three years found upadacitinib beneficial for patients with moderate to severe ulcerative colitis.

In another study, serious side effects were uncommon, occurring in only 3.2% of patients, slightly lower than the 4.5% in a placebo group. No new safety concerns emerged over time, indicating stable safety for the treatment.

Most treatments for ulcerative colitis involve corticosteroids, which can have significant side effects with long-term use. However, upadacitinib is unique because it is a JAK inhibitor, targeting specific pathways in the immune system that are involved in inflammation. This mechanism allows it to potentially reduce symptoms without the need for corticosteroids. Additionally, upadacitinib is taken orally, which can be more convenient and less invasive compared to infusions or injections required by some current therapies. Researchers are excited about upadacitinib because of its potential to offer a safer, more targeted treatment option for patients with ulcerative colitis.

Studies have shown that upadacitinib effectively treats ulcerative colitis (UC). In one study, 81.5% of patients experienced significant symptom improvement or resolution. Another study found that upadacitinib reduced disease activity and UC symptoms over time. Long-term research supports its effectiveness, with about 75% of patients still experiencing relief after three years. Additionally, upadacitinib offers a favorable balance of benefits and risks, with few serious side effects, making it a promising treatment option for people with severe UC. Participants in this trial will receive upadacitinib as a corticosteroid-free induction therapy, followed by protocol-defined post-discharge management and longitudinal follow-up through 52 weeks.²⁵⁶⁷⁸